Effects of Galvanic vestibular stimulation on cognitive function.
Valentina Dilda, Hamish G MacDougall, Ian S Curthoys...
https://pubmed.ncbi.nlm.nih.gov/22076407/Actively Recruiting
Led by Neursantys Inc · Updated on 2025-02-25
500
Participants Needed
4
Research Sites
N/A
Total Duration
This research aims to evaluate the safety, feasibility, effectiveness, and lasting impact of non-invasive electrical vestibular stimulation EVS on balance and walking ability in healthy adults aged 18 to 100 years. It focuses on how EVS influences balance and gait by measuring performance before, during, and after single and repeated sessions at multiple partner sites. The study addresses age-related balance decline, known as presbystasis, which increases fall risk and affects independence, especially in older adults, and explores EVS as a potential non-invasive solution to restore vestibular function and possibly improve cognitive function and headaches. Participants will receive either active treatment with sub-threshold wideband stochastic EVS swsEVS or a sham treatment with no stimulation, in a randomized, single-blind design. The study involves 18 testing sessions over 5 to 6 weeks, where participants undergo EVS while alternating sitting and standing positions with eyes open or closed. Several assessments will be conducted including accelerometer-based gait and balance tests using a smartphone app, clinician-administered Functional Gait Assessments, static and dynamic balance tests, cognitive tests, and questionnaires about headaches and dizziness. Participants will complete balance and gait tests before and after each EVS session, with follow-up visits at 3 weeks, 6 weeks, 3 months, and 6 months post-treatment to evaluate lasting effects. Cognitive assessments and headache questionnaires are done during the first and last treatment sessions. Safety and tolerability are monitored throughout. The main outcomes measured include various balance and gait parameters such as postural sway, gait velocity, cadence, step length, and step trajectory, along with cognitive performance tests, to assess the impact of the stimulation over time.
CONDITIONS
Therapeutic Effects of Electrical Vestibular Stimulation (EVS) on Balance and Gait
R
Ryan M Peters, PhD
J
John D Ralston, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Neursantys Inc
Lead Sponsor
Mitacs
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | EVS (electrical vestibular stimulation) | Sham stimulation (no current) |
|---|---|---|
| What the approach is | A device-based intervention applying low-level electrical currents through electrodes on mastoid areas to activate vestibular nerves. | A sham device setup where no current is delivered, acting as a placebo control. |
| Role in the trial | Study participants receive the active EVS treatment to assess its therapeutic effects. | Participants assigned to the sham arm do not receive stimulation, providing a placebo comparison. |
| Purpose or primary use | Intended to improve balance and gait performance in vestibulopathy. | Serves as a control to compare active EVS effects on balance and gait. |
| Administration or performance | Low‐current electrical stimulation delivered through mastoid‐placed electrodes via a battery‐powered constant‐current stimulator. | Device setup identical but no electrical current applied during use. |
| Evidence status | Therapeutic benefit under investigation; no published evidence within this trial registry. | Placebo comparator, not intended to provide therapeutic benefit. |
| Potential important risks | Not specified; safety profile not described in registry. | Likely minimal risk but not described. |
| Key limitations | Unknown efficacy and safety until trial results are available. | Serves only as control; provides no treatment benefit itself. |
| Patient impact | Impact on balance, gait, or quality of life not yet established; evidence pending trial outcomes. | No direct impact expected; acts as placebo comparison. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 to 6 weeks
Participants receive 18 sessions of electrical vestibular stimulation (swsEVS) or sham stimulation over a 5-6 week period to improve balance and gait performance. Each session includes gait and balance tests before and after a single 20-minute stimulation session.
18 visits (in-person) with gait and balance testing before and after each session
Duration - 6 months
Participants return for follow-up visits at 3 weeks, 6 weeks, 3 months, and 6 months after treatment to repeat gait and balance tests and assess the persistence of any improvements.
4 visits (in-person) at 3 weeks, 6 weeks, 3 months, and 6 months post-treatment
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Valentina Dilda, Hamish G MacDougall, Ian S Curthoys...
https://pubmed.ncbi.nlm.nih.gov/22076407/Julia Dlugaiczyk, Kathrin D Gensberger, Hans Straka
https://pubmed.ncbi.nlm.nih.gov/30995162/Christophe Lopez, Kathleen E Cullen
https://pubmed.ncbi.nlm.nih.gov/37889571/A Deveze, L Bernard-Demanze, F Xavier...
https://pubmed.ncbi.nlm.nih.gov/24502905/Jordan A King, Noah Walters, Nadine Rodrigues...
https://pubmed.ncbi.nlm.nih.gov/41174737/Shinichi Iwasaki, Tatsuya Yamasoba
https://pubmed.ncbi.nlm.nih.gov/25657851/L E Davis
https://pubmed.ncbi.nlm.nih.gov/7963205/Anna Paula Batista de Ávila Pires, Tatiana Rocha Silva, Maíra Soares Torres...
https://pubmed.ncbi.nlm.nih.gov/35915031/Paul F Smith
https://pubmed.ncbi.nlm.nih.gov/38038627/John D Ralston, Ashutosh Raina, Brian W Benson...
https://pubmed.ncbi.nlm.nih.gov/33324120/Neursantys Inc
Lead Sponsor
Mitacs
Collaborating Sponsor